C4 Therapeutics (CCCC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on C4 Therapeutics (CCCC) is Neutral.

The composite score behind that read is -0.08, weighing +0.21 of bullish evidence against -0.25 bearish.

C4 Therapeutics last closed at $3.16, +10.88% on the session.

Against the IVW growth benchmark the position is +10.08% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for CCCC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks C4 Therapeutics in the 19th percentile on return on equity, where 100 is best.

C4 Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $350.62M.

StockMap tracks C4 Therapeutics as the 203rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite C4 Therapeutics ranks 192nd of 381 in the group, against a group median of -0.08.